Minority Health Archive

The ALLHAT Lipid Lowering Trial—Less Is Less

Pasternak, Richard C. (2002) The ALLHAT Lipid Lowering Trial—Less Is Less. JAMA, 288 (23). pp. 3042-3044.

Full text not available from this repository.

Abstract

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Lipid Lowering Trial (ALLHAT-LLT),1 published in this issue of THE JOURNAL, is the second-largest lipid-lowering trial yet reported. This randomized trial, a subset of the larger ALLHAT hypertension study,2 followed up 10 355 patients (49% women) who had hypertension and were 55 years or older for a mean of 4.8 years. Patients were randomly assigned to receive 40 mg of pravastatin (open label) vs "usual care" in 513 clinical centers, the majority of which were community-based. These centers were a subset of the 623 centers that treated patients for the larger (N = 33 357) ALLHAT hypertension study.2 Despite a 28% reduction in low-density lipoprotein cholesterol (LDL-C) from baseline in the pravastatin treatment group, the trial failed to show a benefit in either the primary outcome (all-cause mortality) or the key secondary outcome (combined nonfatal myocardial infarction and . . .


Export/Citation:EndNote | BibTeX | Dublin Core | ASCII (Chicago style) | HTML Citation | OpenURL | Reference Manager
Social Networking:

Item Type: Article
Additional Information: This article is available at the publisher’s Web site. Access to the full text is subject to the publisher’s access restrictions.
Uncontrolled Keywords: lipid-lowering trial; hypertension study; pravastatin
Subjects: Health > Pharmacotherapy
Health > Public Health > Chronic Illness & Diseases > Hypertension
Research > studies
Related URLs:
Depositing User: Users 141 not found.
Date Deposited: 20 Dec 2008
Last Modified: 05 Jul 2011 11:26
Link to this item (URI): http://health-equity.pitt.edu/id/eprint/1256

Actions (login required)

View Item